Certara (NASDAQ:CERT) Trading Down 4.6% – Should You Sell?

Certara, Inc. (NASDAQ:CERT)’s share price traded down 4.6% on Thursday . The stock traded as low as $10.39 and last traded at $10.42. 216,356 shares traded hands during trading, a decline of 74% from the average session volume of 838,846 shares. The stock had previously closed at $10.92.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Barclays reduced their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. Robert W. Baird decreased their target price on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. Finally, UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target for the company in a report on Friday, September 27th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $15.92.

Certara Stock Performance

The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a 50 day moving average price of $10.85 and a two-hundred day moving average price of $12.52. The company has a market cap of $1.71 billion, a price-to-earnings ratio of -53.00, a P/E/G ratio of 5.86 and a beta of 1.53.

Certara (NASDAQ:CERT) last posted its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.02. The company had revenue of $94.80 million during the quarter, compared to analyst estimates of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.06 EPS. Analysts predict that Certara, Inc. will post 0.28 EPS for the current year.

Insider Buying and Selling at Certara

In other Certara news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. This represents a 9.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.39% of the company’s stock.

Institutional Trading of Certara

A number of large investors have recently bought and sold shares of the business. Blue Trust Inc. bought a new position in Certara in the second quarter valued at approximately $26,000. Innealta Capital LLC acquired a new stake in shares of Certara during the second quarter worth $36,000. KBC Group NV lifted its position in Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after acquiring an additional 1,584 shares in the last quarter. Intech Investment Management LLC bought a new position in Certara during the 2nd quarter worth about $152,000. Finally, Algert Global LLC bought a new position in Certara during the 2nd quarter worth about $156,000. 73.96% of the stock is owned by institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.